AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Acronyms GLITTER 2
- Sponsors Gan&Lee Pharmaceuticals
- 28 May 2018 As per Eudra status is Discontinued (Hungary), the record covers all location of the trial however NCT reports recruiting I have retained as per NCT since planned end date is future date.
- 23 May 2018 This trial has been Discontinued in Hungary.
- 15 May 2018 Planned number of patients changed from 554 to 550.